Levomilnacipran for the treatment of major depressive disorder: a review

Levomilnacipran (LVM, Fetzima(®)) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including duloxetine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Asnis, Gregory M, Henderson, Margaret A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295915/
https://www.ncbi.nlm.nih.gov/pubmed/25657584
http://dx.doi.org/10.2147/NDT.S54710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295915/
https://www.ncbi.nlm.nih.gov/pubmed/25657584
http://dx.doi.org/10.2147/NDT.S54710

Ejemplares similares